Sequencing Checkpoint Inhibitors in NSCLC

For High-Definition, Click

With PD-1 inhibitors rapidly becoming available for patients with non-small cell lung cancer, the next questions facing researchers will be optimal sequences for these agents with targeted therapies. In patients with EGFR mutations, where a response to a TKI is expected, starting with a PD-1 inhibitor could result in better outcomes. However, some might reserve the PD-1 inhibitor until resistance occurs.

As clinical trials begin to show the benefits associated with PD-1 inhibitors in NSCLC, the need for a better biomarker will be enhanced.

View the video, to hear the discussion.